Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that Wild type ALK, Wild type EGFR status confers therapeutic sensitivity to Carboplatin, Ipilimumab, Nivolumab, Pemetrexed in patients with Non-Small Cell Lung Cancer.
This statement is based on a regulatory approval from the Health Service Executive:
First-line treatment of metastatic non-small cell lung cancer (NSCLC) in adults whose tumours have no sensitising EGFR mutation or ALK translocation.